خبر
قبل ساعة واحدةملخص الذكاء الاصطناعي
Novo Nordisk Shareholders Sue Over Obesity Drug CagriSema Trial Disclosure
Novo Nordisk faces a lawsuit from shareholders alleging misleading statements about its obesity drug CagriSema's clinical trial, leading to a significant market value drop. A federal judge has allowed parts of the lawsuit to proceed.
C
CNBC World5 د قراءة